Dale Geoffrey Schaar MD PhD

Hematologic Oncology

Professor of Medicine Department of Medicine Rutgers Medical School Rutgers University Director of Myeloid Malignancies Attending, Blood and Marrow Transplant Rutgers Cancer Institute of New Jersey

Join to view full profile

165 Somerset StreetNew Brunswick, NJ 08901

Dr. Schaar is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schaar's full profile Already have an account?

Education & Training

Rutgers Health/Robert Wood Johnson Medical SchoolFellowship, Hematology and Medical Oncology, 1999 - 2003
University of MarylandResidency, Internal Medicine, 1997 - 1999
Rutgers Robert Wood Johnson Medical SchoolClass of 1997
University of Medicine and Dentistry of New Jersey/Rutgers UniversityPh.D., Microbiology (joint degree), 1991
Cook College, Rutgers UniversityB.A., Biochemistry, 1984

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NJ State Medical License 1999 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Patient Engagement Portal, Navigating Cancer, Inc., 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017

Clinical Trials

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
ACTIVE_NOT_RECRUITING
PHASE3

Publications & Presentations

PubMed

4 citations
Prophylactic Vancomycin in the Primary Prevention of Clostridium difficile in Allogeneic Stem Cell Transplant.
Brendon Fusco, Jasmine Tomita-Barber, Natale Mazzaferro, Anne Tyno, Nicole McEntee
Transplant Infectious Disease. 2025-03-18
19 citations
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
Keri R Maher, Danielle Shafer, Dale Schaar, Dipankar Bandyopadhyay, Xiaoyan Deng
Cancer Chemotherapy and Pharmacology. 2025-01-17
4 citations
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results ...
Neil D Palmisiano, Ju-Whei Lee, David F Claxton, Elisabeth M Paietta, Hassan Alkhateeb
Ejhaem. 2024-10-01

Journal Articles

PDCD2 functions in cancer cell proliferation and predicts relapsed leukemia
Barboza, N., Minakhina, S., Medina, D.J., Balsara, B., Greenwood, S., Huzzy, L., Rabson, A.B., Steward, R. and Schaar, D.G., Cancer Biol Ther, 6/1/2013
A Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M, Cancer, 4/1/2012
Accelerated R-COP: A Pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate
Levitt, M.J., Gharibo, M., Strair, R., Schaar, D., Rubin, A. and Bertino, J.R., J Chemotherapy, 1/1/2009

Abstracts/Posters

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution S...
Dale Schaar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Dual-Specificity MAPK Phosphatases (DS-MKPs): novel targets for AML therapy.
Schaar, D.G., Ting, Y. and Strair, R., Annual Workshop on Cancer Research in New Jersey, The New Jersey Commission on Cancer Research, 1/1/2006
Novel Strategies Targeting Pro-Survival Pathways in AML.
Schaar, D.G., Liu, H., Sharma, S., Ting, Y., Martin, J., Krier, C., Ciardella, M., Osman, M., Goodell, L., Notterman, D.A. and Strair, R., Annual Workshop on Cancer Research in New Jersey, The New Jersey Commission on Cancer Research, 1/1/2005

Other

The expression of a murine cytotoxic T-cell receptor and the lymphokine, interleukin-2, as a result of retrovirus-mediated gene transfer. Ph.D. Thesis.
Schaar, D.G.
1/1/1991